Patents Assigned to Sunshine Lake Pharma Co., Ltd.
  • Substituted piperazine compounds and methods of use and use thereof
    Patent number: 10316025
    Abstract: The invention relates to substituted piperazine compounds and methods of use and uses thereof, and further to the pharmaceutical compositions comprising the compounds and uses thereof, wherein the compound has Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The substituted piperazine compounds and pharmaceutical compositions comprising the compounds disclosed herein can be used for inhibiting 5-hydroxytryptamine reuptake and/or stimulating 5-HT1A receptors. The invention also relates to processes for preparing these compounds and pharmaceutical compositions, and their uses in the treatment of a central nervous system dysfunction.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: June 11, 2019
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Chuanfei Jin, Haiping Liang, Chao Yi, Ji Zhang
  • NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
    Publication number: 20190169203
    Abstract: A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the use of the compound for the treatment of disease and/or condition mediated by FXR are described. And a pharmaceutical composition containing the compound disclosed herein and a method of treatment of disease and/or condition mediated by FXR comprising administering the compound or the pharmaceutical composition thereof are also described.
    Type: Application
    Filed: August 2, 2017
    Publication date: June 6, 2019
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xiaojun WANG, Xinye YANG, Junwen WU, Shaohui XIONG, Shengqiang PAN, Shengtian CAO, Yingjun ZHANG
  • Salt of EGFR inhibitor, crystalline form and uses thereof
    Patent number: 10308658
    Abstract: The invention relates to a salt, a hydrate or a crystalline form of an EGFR inhibitor, and use thereof. Specifically it relates to 4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-[3-[(1R,6S)-2,5-dioxa-8-azabicyclo [4.3.0] nonan-8-yl] propoxy] quinazoline dimethanesulfonate, hydrate and a crystalline form thereof; the invention also relates to a preparation method of the crystalline form disclosed herein, a pharmaceutical composition containing the crystalline form, and uses thereof for treating proliferative disorders.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: June 4, 2019
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Bing Liu, Weihong Zhang, Yingjun Zhang
  • Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof
    Patent number: 10266496
    Abstract: Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine oxidase and urate anion transporter 1, and also can be used in the treatment or prevention of diseases associated with high blood uric acid level in mammals, especially humans.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: April 23, 2019
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xinye Yang, Changwei Huang, Facheng Ma, Ji Zhang, Xiaojun Wang, Yingjun Zhang
  • Substituted heteroaryl compounds and methods of use
    Patent number: 10266521
    Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: April 23, 2019
    Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Wuhong Chen, Tao Zhang, Haiyang Hu, Weilong Dai, Yanjun Wu
  • Cell culture medium and methods for enhancing recombinant antibody purity
    Patent number: 10196665
    Abstract: This invention relates to a novel cell culture medium and methods to enhance recombinant antibody purity using the cell culture medium disclosed herein. The novel cell culture medium is a self-made feeding medium, which comprises from about 90 nM to about 500 mM cysteine, from about 50 mM to about 500 mM tyrosine, and from about 50 mM to about 300 tryptophan. This invention also relates to a method of growing cell culture using the cell culture medium disclosed herein By controlling the concentration of cysteine in the self-made feed medium as well as the amount and time of adding this feed medium into the cell culture, the purity of antibodies is significantly improved while glycosylation profile and antibody expression level are consistently maintained to guarantee the efficacy of antibodies.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: February 5, 2019
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xiwen Cheng, Chengwei Yan, Bin Yang, Wen-Chen Suen, Yuancan Weng, Chongfei Deng
  • Substituted quinazoline compounds and preparation and uses thereof
    Patent number: 10196383
    Abstract: The present invention relates quinazolinone compounds of Formula (I), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses; wherein the compounds or pharmaceutical compositions disclosed herein can be used for antagonizing the orexin receptor. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing neurological and psychiatric disorders and diseases of the central nervous system in mammals, especially in humans.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: February 5, 2019
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Chuanfei Jin, Jinheng Gao, Ji Zhang
  • APIXABAN SOLID COMPOSITION AND PREPARATION METHOD THEREOF
    Publication number: 20190022008
    Abstract: The present invention provided an apixaban solid composition and a preparation method thereof. The method comprises granulating apixaban by wet granulation, wherein the apixaban has a particle size D90 more than 89 ?m.
    Type: Application
    Filed: January 11, 2017
    Publication date: January 24, 2019
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Qibiao HUANG, Xin HUANG, Fangfang HUANG, Jinsong YOU, Feng ZHAO
  • Tricyclic compounds and uses thereof in medicine
    Patent number: 10183917
    Abstract: The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the uses of the compounds for the treatment of diseases and/or conditions mediated by FXR. The invention further provides a pharmaceutical composition containing the compound disclosed herein and a method of treatment of diseases and/or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: January 22, 2019
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xiaojun Wang, Xinye Yang, Shengqiang Pan, Rui Guo, Junwen Wu, Yingjun Zhang, Changchung Cheng
  • SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF
    Publication number: 20180362439
    Abstract: The present invention relates to a sacubitril intermediate and a preparation method thereof. The sacubitril intermediate disclosed herein can be prepared by a deprotection reaction of a compound. In addition, the intermediate can be used as a raw material to synthesize sacubitril. The method disclosed herein has advantages of easily obtained raw materials, simple preparation process, low cost, environment friendly, and etc., which is very suitable for industrial production.
    Type: Application
    Filed: August 26, 2018
    Publication date: December 20, 2018
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Lei CHEN, Guodong SUN, Xiaodong HAN, Shun LI, Jiebin ZENG, Zhongqing WANG, Zhonghua LUO
  • COMPLEX OF A GLUCOPYRANOSYL DERIVATIVE AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20180344689
    Abstract: This present invention relates to a complex of a glucopyranosyl derivative and L-pyroglutamic acid as a sodium dependent glucose cotransporter (SGLT) inhibitor, and preparation processes thereof, and a pharmaceutical composition containing the complex, and their uses in the manufacture of a medicament for treating diabetes and/or diabetes-related diseases.
    Type: Application
    Filed: November 28, 2016
    Publication date: December 6, 2018
    Applicant: Sunshine Lake Pharma Co., Ltd.
    Inventors: Pengcho TANG, Zheng GU, Wuyong WU, Zongyuan ZHANG, Panpan KANG, Tong QU
  • INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF
    Publication number: 20180346463
    Abstract: The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
    Type: Application
    Filed: December 8, 2016
    Publication date: December 6, 2018
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun ZHANG, Qingyun REN, Changhua TANG, Xiaohong LIN, Junjun YIN, Kai YI
  • OCTAHYDROPYRROLO[3,4-c]PYRROLE DERIVATIVES AND USES THEREOF
    Publication number: 20180334460
    Abstract: The invention relates to octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof. Compounds and pharmaceutical compositions comprising the compounds provided herein are used for antagonizing orexin receptors. The invention also relates to processes for preparing the compounds and pharmaceutical compositions, and uses thereof in treating or preventing a disease related to orexin receptors.
    Type: Application
    Filed: November 23, 2016
    Publication date: November 22, 2018
    Applicant: Sunshine Lake Pharma Co., Ltd.
    Inventors: Yingjun ZHANG, Chuanfei JIN, Ji ZHANG
  • A SALT OF EGFR INHIBITOR, CRYSTALLINE FORM AND USES THEREOF
    Publication number: 20180298019
    Abstract: The invention relates to a salt, a hydrate or a crystalline form of an EGFR inhibitor, and use thereof. Specifically it relates to 4-[(3-chloro-4-fluorophenyl) amino]-7-methoxy-6-[3-[(1R,6S)-2,5-dioxa-8-azabicyclo [4.3.0] nonan-8-yl] propoxy]quinazoline dimethanesulfonate, hydrate and a crystalline form thereof; the invention also relates to a preparation method of the crystalline form disclosed herein, a pharmaceutical composition containing the crystalline form, and uses thereof for treating proliferative disorders.
    Type: Application
    Filed: October 18, 2016
    Publication date: October 18, 2018
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Bing LIU, Weihong ZHANG, Yingjun ZHANG
  • Complexes and salts of dihydropyrimidine derivatives and their application in pharmaceuticals
    Patent number: 10098889
    Abstract: This invention relates to L-tartaric acid complexes, acid addition salts, base addition salts of the compound named (S)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl) morpholine-3-carboxylic acid or tautomer thereof and pharmaceutical compositions thereof, and further relates to use of the compounds or the pharmaceutical compositions in the manufacture of a medicament, especially for use in preventing, managing, treating or lessening a HBV infection. The complex, acid addition salt or base addition salt of the present invention is crystalline form, substantially crystalline form, polymorphism, amorphism, hydrate or solvate.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: October 16, 2018
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Qingyun Ren, Liang Chen, Xinchang Liu, Jinsheng Liang, Chenliang Wu, Zhifu Zou, Guanghua Yan, Desheng Huangfu, Siegfried Goldmann, Yingjun Zhang
  • COMPLEXES AND SALTS OF DIHYDROPYRIMIDINE DERIVATIVES AND THEIR APPLICATION IN PHARMACEUTICALS
    Publication number: 20180263991
    Abstract: This invention relates to L-tartaric acid complexes, acid addition salts, base addition salts of the compound named (S)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl) methyl) morpholine-3-carboxylic acid or tautomer thereof and pharmaceutical compositions thereof, and further relates to use of the compounds or the pharmaceutical compositions in the manufacture of a medicament, especially for use in preventing, managing, treating or lessening a HBV infection. The complex, acid addition salt or base addition salt of the present invention is crystalline form, substantially crystalline form, polymorphism, amorphism, hydrate or solvate.
    Type: Application
    Filed: February 1, 2016
    Publication date: September 20, 2018
    Applicant: SUNSHINE LAKE PHARMA CO., LTD
    Inventors: Qingyun Ren, Liang CHEN, Xinchang LIU, Jinsheng LIANG, Chenliang WU, Zhifu ZOU, Guanghua YAN, Desheng HUANGFU, Siegfried GOLDMANN, Yingjun ZHANG
  • Substituted urea derivatives and pharmaceutical uses thereof
    Patent number: 10065934
    Abstract: Provided herein are novel substituted urea derivatives, and pharmaceutical compositions thereof. Also provided herein are uses of the compounds or pharmaceutical compositions thereof for preventing, managing, treating or lessening a proliferative disease, and modulating the activity of protein kinase.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: September 4, 2018
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Changchung Cheng, Yingjun Zhang, Bing Liu, Bohua Long, Yu Chen, Zhixin Cheng
  • Quinolinone compound and use thereof
    Patent number: 10065928
    Abstract: Provided herein are a quinolinone compound, pharmaceutical composition thereof, and use of the compound or the pharmaceutical composition in drug preparation, the drug being used to prevent, manage, treat or relieve diseases related to HIF and/or EPO of a patient, including anemia, vascular disease, myocardial ischemia, dysmetabolism, or for wound healing.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: September 4, 2018
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yinglin Zuo, Xiaojun Wang, Yingjun Zhang, Liang Wen, Shoutao Wu, Xiaofeng Yuan
  • Substituted heteroaryl compounds and methods of use
    Patent number: 10059689
    Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.
    Type: Grant
    Filed: October 10, 2015
    Date of Patent: August 28, 2018
    Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Weilong Dai, Haiyang Hu, Tao Zhang, Wuhong Chen
  • CARBOXY SUBSTITUTED (HETERO) AROMATIC RING DERIVATIVES AND PREPARATION METHOD AND USES THEREOF
    Publication number: 20180230102
    Abstract: Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine oxidase and urate anion transporter 1, and also can be used in the treatment or prevention of diseases associated with high blood uric acid level in mammals, especially humans.
    Type: Application
    Filed: August 31, 2016
    Publication date: August 16, 2018
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xinye YANG, Changwei HUANG, Facheng MA, Ji ZHANG, Xiaojun WANG, Yingjun ZHANG